Daily IPO Digest
Daily Digest — September 11, 2026
Published
Not financial or investment advice, and not a solicitation to buy or sell any security or to use our service. This is AI-assisted analysis of public SEC filings, provided for informational purposes only. It is generated by an automated pipeline with no human review and will likely contain factual errors, interpretive errors, and errors of omission that misrepresent the business or the offering. Do not rely on it as the sole basis for any investment decision. Always do your own research.
Just Filed
Hometown Financial Group
No ticker yet · Thrift conversion · $510 million to $793.5 million · Nasdaq
A century-and-a-half-old Massachusetts mutual savings bank — founded in 1,869 — is converting to stock form and filing to raise between $510 million and $793.5 million at $10.00 per share, while simultaneously acquiring a merger partner and retiring $135 million in senior debt. The institution behind the offering, TruNorth Bank, enters the conversion with $6.94 billion in total assets, $5.32 billion in net loans, and a loan book that is 92.7% real estate-based — heavy on one-to-four family residential (37.3%) and commercial real estate (34.3%).
The filing's most load-bearing disclosure is a credit loss provision that jumped to $39.3 million in the most recent fiscal year from $10.7 million the year prior — absorbing most of the improvement in net interest income and pulling net income down to $43.4 million from $47.9 million. Non-performing assets stand at $82.8 million, and uninsured deposits total $1.85 billion. The offering is priced at a 59.5% discount to peer price-to-tangible book — a real gap, but one the provision trajectory helps explain. The institution has executed eight acquisitions over the past eleven years and is folding in another at roughly $160 million in total consideration as part of this conversion. Terms not final; this is a subscription offering that requires a minimum of 51 million shares sold to close.
Allarity Acquisition Corp.
ALLN · Initial S-1 · filed to raise up to $100 million (up to $115 million with greenshoe) · Nasdaq
A blank-check vehicle sponsored by Allarity Therapeutics — a clinical-stage biotech — seeking $100 million in trust via 10 million units at $10 per unit. The unusual detail here is the sponsor structure: Allarity Therapeutics holds 99.9% of the voting interest in the sponsor, meaning the people hunting for a merger target are also running a listed micro-cap biotech. The SPAC has a short runway — a maximum of 185 days to complete a business combination — while standard vehicles typically run considerably longer. Founder shares were purchased for $25,000 total; the sponsor's total investment at closing is $1,875,000. Warrants are exercisable at $11.50 per share. Net tangible book value per share at no redemption is $7.29, implying the usual dilution gap relative to the $10 offer price. The conflict between managing a public biotech and running a SPAC acquisition search is structural and disclosed plainly.
Elevation Acquisition Group
No ticker yet · Initial S-1 · filed to raise up to $100 million (up to $115 million with greenshoe) · Nasdaq
Another $100 million blank-check vehicle, this one with a longer combination window — 540 days — and a more textured macro thesis than most SPAC filings. The risk-factor section leans heavily on energy-infrastructure disruption, citing the Strait of Hormuz as carrying 20% of global seaborne oil trade as framing for its deal-hunting target profile. The CEO brings 35 years of business experience including $4 billion in aggregate M&A transaction value. The filing also discloses the track record of affiliated prior SPACs — one of which (RNER) saw 99.69% of its public shares redeemed, a figure that frames what "successful" can look like for SPAC trust capital. Founder shares were acquired for $25,000; aggregate insider investment at closing is $3,175,000. Units price at $10; terms not final.
Rafex Gold Corp.
RAFX · Initial S-1 · resale registration · zero proceeds to company
Rafex Gold is not raising capital. It is registering 22,667,672 shares at $0.25 per share for resale by existing selling shareholders — total estimated proceeds to sellers of $5,666,918, none flowing to the company itself. The filing expenses run to $36,587. The company carries zero revenue, a net loss of $152,817 in its most recent fiscal year, cash on hand of $31,715, total assets of $733,576 against total liabilities of $1,816,048, and a stockholders' deficit of $1,082,472. The going-concern accumulated deficit stands at $2,645,094. Two insiders — Brimage and Davies — together control 78.4% of total voting power; all directors and officers combined hold 86.43% of the vote, leaving public shareholders with 13.57%. The Australian gold exploration assets include a Rutherglenn tenement with an exploration target of 300,000 ounces and a Bendoc resource estimate of 94,000 ounces. Gold prices remain elevated — the filing cites an August 2026 range of $3,922 to $4,171 per ounce — but the company has no production, its exploration budget depends on further related-party financing, and this filing creates a liquidity window for insiders, not a capital raise for the business.
Sources
Regulatory filings
- SEC filings